{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T01:50:13Z","timestamp":1791856213846,"version":"4.3.4"},"reference-count":26,"publisher":"Public Library of Science (PLoS)","issue":"5","license":[{"start":{"date-parts":[[2022,5,12]],"date-time":"2022-05-12T00:00:00Z","timestamp":1652313600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Dr. August Wolff GmbH & Co. KG Arzneimittel"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:p>This prospective, open-label, multicentre, multinational, randomised trial investigated the non-inferiority of treatment with a vaginal hormone-free moisturising cream compared to a vaginal estriol (0.1%) cream in a panel of post-menopausal women suffering from symptoms of vulvovaginal dryness in a parallel group design. In total, 172 post-menopausal women were randomly allocated to either one of the two treatments, each administered for 43 days. The primary endpoint was the total severity score of subjective symptoms (dryness, itching, burning and pain unrelated to sexual intercourse) of the respective treatment period. Secondary endpoints were severity of single subjective symptoms (including dyspareunia if sexually active), impairment of daily life, Vaginal Health Index, as well as assessment of safety. In both groups, women treated with hormone-free moisturising cream and those treated with estriol cream, total severity score improved significantly compared to baseline by 5.0 (from 6.1 to 1.1) and by 5.4 (from 6.0 to 0.6), respectively, after 43 days of treatment (p &lt; 0.0001). One-sided test of baseline differences (for a clinically relevant difference \u0394 = 1.5) confirmed the hormone-free moisturising cream to be non-inferior to the estriol cream. Severity of dyspareunia as well as impairment of daily life due to subjective symptoms, significantly improved for both treatment groups (p&lt;0.0001). Subgroup analysis of women with mild or moderate impairment of daily life at baseline caused by \u201cvaginal dryness\u201d symptoms benefited from both creams, while women with severe impairment showed a significantly greater benefit from the estriol cream (p = 0.0032). Both treatments were well tolerated with no serious adverse events occurring. This study provides clinical evidence that a hormone-free vaginal moisturising cream cannot only improve vaginal dryness compared to an 0.1% estriol cream but also can relieve dyspareunia as well as improve woman\u2019s impairment of daily life, justifying its use as a first choice for mild or moderate vulvovaginal dryness symptoms.<\/jats:p>","DOI":"10.1371\/journal.pone.0266633","type":"journal-article","created":{"date-parts":[[2022,5,12]],"date-time":"2022-05-12T17:39:08Z","timestamp":1652377148000},"page":"e0266633","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":15,"title":["Vaginal hormone-free moisturising cream is not inferior to an estriol cream for treating symptoms of vulvovaginal atrophy: Prospective, randomised study"],"prefix":"10.1371","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4935-8989","authenticated-orcid":true,"given":"Susana","family":"Garcia de Arriba","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Gr\u00fcntkemeier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel","family":"H\u00e4user","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theodor W.","family":"May","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clarissa","family":"Masur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petra","family":"Stute","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2022,5,12]]},"reference":[{"issue":"10","key":"pone.0266633.ref001","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1097\/GME.0000000000000329","article-title":"Vulvovaginal Atrophy Terminology Consensus Conference P. Genitourinary syndrome of menopause: new terminology for vulvovaginal atrophy from the International Society for the Study of Women\u2019s Sexual Health and the North American Menopause Society","volume":"21","author":"DJ Portman","year":"2014","journal-title":"Menopause"},{"issue":"Suppl 1","key":"pone.0266633.ref002","doi-asserted-by":"crossref","first-page":"S46","DOI":"10.1016\/j.maturitas.2005.06.014","article-title":"Management of post-menopausal vaginal atrophy and atrophic vaginitis","volume":"52","author":"C Castelo-Branco","year":"2005","journal-title":"Maturitas"},{"issue":"1","key":"pone.0266633.ref003","doi-asserted-by":"crossref","first-page":"87","DOI":"10.4065\/mcp.2009.0413","article-title":"Vulvovaginal atrophy","volume":"85","author":"M B Mac Bride","year":"2010","journal-title":"Mayo Clinic proceedings"},{"issue":"10","key":"pone.0266633.ref004","doi-asserted-by":"crossref","first-page":"615","DOI":"10.3390\/medicina55100615","article-title":"Vaginal Health in Menopausal Women","volume":"55","author":"S Alvisi","year":"2019","journal-title":"Medicina (Kaunas)"},{"issue":"4","key":"pone.0266633.ref005","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.maturitas.2015.05.007","article-title":"Characteristics of post-menopausal women with genitourinary syndrome of menopause: Implications for vulvovaginal atrophy diagnosis and treatment selection","volume":"81","author":"C Castelo-Branco","year":"2015","journal-title":"Maturitas"},{"issue":"4 Pt 1","key":"pone.0266633.ref006","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1097\/gme.0b013e31815a5168","article-title":"Vulvovaginal atrophy is strongly associated with female sexual dysfunction among sexually active postmenopausal women","volume":"15","author":"KB Levine","year":"2008","journal-title":"Menopause"},{"issue":"5","key":"pone.0266633.ref007","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1097\/GME.0000000000001260","article-title":"The burden of vulvovaginal atrophy on women\u2019s daily living: implications on quality of life from a face-to-face real-life survey","volume":"26","author":"RE Nappi","year":"2019","journal-title":"Menopause"},{"issue":"9","key":"pone.0266633.ref008","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1097\/GME.0000000000001609","article-title":"The 2020 genitourinary syndrome of menopause position statement of The North American Menopause Society","volume":"27","year":"2020","journal-title":"Menopause"},{"key":"pone.0266633.ref009","doi-asserted-by":"crossref","first-page":"281","DOI":"10.2147\/IJWH.S57900","article-title":"Postmenopausal vaginal atrophy: Evaluation of treatment with local estrogen therapy","volume":"6","author":"MJ Minkin","year":"2014","journal-title":"Int. J. Womens. Health"},{"issue":"2","key":"pone.0266633.ref010","doi-asserted-by":"crossref","first-page":"182","DOI":"10.3109\/13697137.2014.975198","article-title":"Ultra-low dose\u2014new approaches in menopausal hormone therapy","volume":"18","author":"P Stute","year":"2015","journal-title":"Climacteric"},{"key":"pone.0266633.ref011","doi-asserted-by":"crossref","first-page":"387","DOI":"10.2147\/IJWH.S158913","article-title":"Current treatment options for postmenopausal vaginal atrophy","volume":"10","author":"I Naumova","year":"2018","journal-title":"Int J Womens Health"},{"issue":"6","key":"pone.0266633.ref012","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1111\/aji.12230","article-title":"The structure of the human vaginal stratum corneum and its role in immune defense","volume":"71","author":"DJ Anderson","year":"2014","journal-title":"American journal of reproductive immunology (New York, NY: 1989)"},{"issue":"5","key":"pone.0266633.ref013","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1111\/jdv.12864","article-title":"Use of emollients in atopic dermatitis","volume":"29","author":"J Ng","year":"2015","journal-title":"Journal of the European Academy of Dermatology and Venereology"},{"issue":"4","key":"pone.0266633.ref014","doi-asserted-by":"crossref","first-page":"582","DOI":"10.3109\/13697137.2015.1036854","article-title":"Efficacy and safety of non-hormonal remedies for vaginal dryness: open, prospective, randomized trial","volume":"18","author":"P Stute","year":"2015","journal-title":"Climacteric"},{"issue":"1","key":"pone.0266633.ref015","doi-asserted-by":"crossref","first-page":"e0210967","DOI":"10.1371\/journal.pone.0210967","article-title":"Topical treatment of vaginal dryness with a non-hormonal cream in women undergoing breast cancer treatment\u2014An open prospective multicenter study","volume":"14","author":"D Chatsiproios","year":"2019","journal-title":"PLoS One"},{"issue":"24","key":"pone.0266633.ref016","doi-asserted-by":"crossref","first-page":"2594","DOI":"10.1001\/jama.2012.87802","article-title":"Reporting of noninferiority and equivalence randomized trials: extension of the CONSORT 2010 statement","volume":"308","author":"CONSORT Group","year":"2012","journal-title":"JAMA"},{"key":"pone.0266633.ref017","unstructured":"FDA, Non-Inferiority Clinical Trials to Establish Effectiveness. Guidance for Industry. 2016. Available from: Non-Inferiority Clinical Trials to Establish Effectiveness Guidance for Industry (fda.gov)"},{"issue":"2","key":"pone.0266633.ref018","doi-asserted-by":"crossref","first-page":"151","DOI":"10.3109\/13697137.2015.1124259","article-title":"Treating vulvovaginal atrophy\/genitourinary syndrome of menopause: how important is vaginal lubricant and moisturizer composition?","volume":"19","author":"D Edwards","year":"2016","journal-title":"Climacteric"},{"key":"pone.0266633.ref019","unstructured":"World Health Organization. Use and procurement of additional lubricants for male and female condoms: WHO\/UNFPA\/FHI360 advisory note 2012 [7 July 2015]. Available from: http:\/\/apps.who.int\/iris\/bitstream\/10665\/76580\/1\/WHO_RHR_12.33_eng.pdf"},{"key":"pone.0266633.ref020","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/0378-5122(95)00956-6","article-title":"Urogenital ageing: an old problem newly recognized","volume":"22","author":"G. Bachmann","year":"1995","journal-title":"Maturitas"},{"issue":"1","key":"pone.0266633.ref021","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1097\/01.GME.0000077620.13164.62","article-title":"Efficacy of low-dose intravaginal estriol on urogenital aging in postmenopausal women","volume":"11","author":"S Dessole","year":"2004","journal-title":"Menopause"},{"key":"pone.0266633.ref022","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/0378-5122(80)90029-8","article-title":"The treatment of postmenopausal vaginal atrophy with Ovestin vaginal cream or suppositories: clinical, endocrinological and safety aspects","volume":"2","author":"PM Kicovic","year":"1980","journal-title":"Maturitas"},{"key":"pone.0266633.ref023","first-page":"101","article-title":"Ovestin vaginal cream and suppositories for the treatment of menopausal vaginal atrophy","volume":"6","author":"R Trevoux","year":"1982","journal-title":"Reproduccion"},{"issue":"6","key":"pone.0266633.ref024","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1097\/AOG.0000000000000526","article-title":"Society of Gynecologic Surgeons Systematic Review Group. Vaginal estrogen for genitourinary syndrome of menopause: a systematic review","volume":"124","author":"DD Rahn","year":"2014","journal-title":"Obstet Gynecol"},{"issue":"8","key":"pone.0266633.ref025","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1080\/09513590.2021.1943346","article-title":"Management of postmenopausal vulvovaginal atrophy: recommendations of the International Society for the Study of Vulvovaginal Disease","volume":"37","author":"FR P\u00e9rez-L\u00f3pez","year":"2021","journal-title":"Gynecol Endocrinol"},{"issue":"4 Pt 2","key":"pone.0266633.ref026","first-page":"722","article-title":"Meta-analysis of estrogen therapy in the management of urogenital atrophy in postmenopausal women: second report of the Hormones and Urogenital Therapy Committee","volume":"92","author":"L Cardozo","year":"1998","journal-title":"Obstet Gynecol"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0266633","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,12]],"date-time":"2022-05-12T17:39:34Z","timestamp":1652377174000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0266633"}},"subtitle":[],"editor":[{"given":"Walid Kamal","family":"Abdelbasset","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2022,5,12]]},"references-count":26,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2022,5,12]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0266633","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,12]]}}}